Overview
- Topline results from a randomized, double-blind, placebo-controlled Chinese phase 2 trial (n=205) showed up to 19.7% mean weight loss at 24 weeks versus 2.0% with placebo from a 92.2 kg baseline.
- Investigators reported a tolerability profile consistent with incretin therapies, with mostly mild to moderate gastrointestinal events that diminished over time.
- All dose groups achieved statistically significant improvements on key secondary measures, including waist circumference, blood glucose, blood pressure and lipids compared with placebo.
- United Biotechnology will present detailed phase 2 data at a medical congress and plans to start a China phase 3 later in 2026.
- Novo Nordisk has begun a separate global phase 1b/2a study (~330 participants, up to 28 weeks) with topline data expected in 2027, aims to start a type 2 diabetes phase 2 in H2 2026, and holds rights outside Greater China under a March 2025 deal reported at up to $2 billion.